Milla Pharmaceuticals, US subsidiary of the A.forall Group, is proud to announce the expansion of A.forall’s generics portfolio in the US market.
With the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm’s US portfolio, we strengthen our presence in hospitals across the country, reinforcing our commitment to high-quality, accessible medicines.
With strong commercial integration, growing partnerships and a dedicated US team, we continue to play a key role in A.forall’s renewed global strategy.
🔗 Read the full press release
📽️ Watch the video message from Steen Vangsgaard, CEO of A.forall
.